Maxcyte (MXCT) Common Equity (2020 - 2026)

Maxcyte (MXCT) has 7 years of Common Equity data on file, last reported at $167.9 million in Q1 2026.

• On a quarterly basis, Common Equity fell 15.81% year-over-year to $167.9 million in Q1 2026; TTM through Mar 2026 was $167.9 million, a 15.81% decrease from a year earlier, with the FY2025 full-year figure at $171.5 million, down 16.85% from the prior year.
• Common Equity for Q1 2026 stood at $167.9 million, down from $171.5 million in the prior quarter.
• Over the last five years, Common Equity for MXCT reached as high as $262.2 million in Q1 2022 and fell as low as $167.9 million in Q1 2026.
• Historically, Common Equity has averaged $221.1 million across 5 years, with a median of $226.4 million in 2024.
• Across the five-year window, Common Equity surged 226.34% in 2022 and retreated 16.85% in 2025, its largest moves.
• Year by year, Common Equity stood at $254.0 million in 2022, then retreated by 8.58% to $232.2 million in 2023, then slipped by 11.16% to $206.3 million in 2024, then slipped by 16.85% to $171.5 million in 2025, then dropped by 2.1% to $167.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $167.9 million in Q1 2026, $171.5 million in Q4 2025, and $180.3 million in Q3 2025.